Stay updated on AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial

Sign up to get notified when there's something new on the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The study has expanded to include 22 locations, and the website has been updated to version v2.10.0, replacing the previous version v2.9.7.
    Difference
    0.5%
    Check dated 2024-07-23T14:34:08.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:31:58.000Z thumbnail image
  7. Check
    16 days ago
    Change Detected
    Summary
    The website now displays the actual last update posted instead of an estimated time, providing users with more accurate information.
    Difference
    0.1%
    Check dated 2024-07-11T00:36:58.000Z thumbnail image
  8. Check
    17 days ago
    Change Detected
    Summary
    The website has added new locations in Nashville, Tennessee, including the Vanderbilt University Medical Center Clinical Research Center and the Vanderbilt Hemostasis Treatment Clinic, with the last update posted on July 8th.
    Difference
    3%
    Check dated 2024-07-09T23:55:41.000Z thumbnail image
  9. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T12:52:07.000Z thumbnail image
  10. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content related to the study of Recombinant AAV2/​6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A, specifically focusing on the safety, tolerability, and time-course profile of FVIII activity after dosing with SB-525 (PF-07055480).
    Difference
    0.1%
    Check dated 2024-06-27T09:23:04.000Z thumbnail image

Stay in the know with updates to AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page.